GlassScriptPhysician profile
Mark Christopher Martindale
NPI 1508416785
$5,289.37
in general payments reported to CMS, 2019-2025
43 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,482 · 2022: $727 · 2023: $490 · 2024: $1,208 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.13 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.63 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $457.32 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $301.60 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $293.45 | 2021-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $268.28 | 2021-2025 | Trintellix |
| Novo Nordisk INC | $239.11 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.13 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $195.78 | 2024-2025 | Auvelity, Symbravo |
| Pfizer INC. | $180.22 | 2021-2025 | |
| Alkermes, INC. | $175.15 | 2024-2025 | Lybalvi, Aristada |
| Corcept Therapeutics | $141.04 | 2021-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $106.32 | 2021-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $105.22 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $98.69 | 2021-2022 | |
| Amgen INC. | $97.23 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Martindale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.